Online inquiry

IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10520MR)

This product GTTS-WQ10520MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10520MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3093MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ8518MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ13405MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ10222MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ1036MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ3917MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ5345MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ724MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-623
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW